SHR 0534Alternative Names: SHR0534
Latest Information Update: 02 Jan 2017
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 01 Jan 2016 Jiangsu HengRui Medicine Co completes a phase I trial in Healthy volunteers in China (PO) (NCT02750553)